Positive results for selinexor in advanced unresectable dedifferentiated liposarcoma

Manufacturers report that in the phase III SEAL study, selinexor (an oral Selective Inhibitor of Nuclear Export [SINE] compound) improved the progression free survival by 30% compared to placebo.

Biospace Inc.